- Home
- SKYE vs FINS Comparison
SKYE vs FINS Comparison
Compare SKYE & FINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- FINS
- Stock Information
- Founded
- SKYE 2012
- FINS 2019
- Country
- SKYE United States
- FINS United States
- Employees
- SKYE N/A
- FINS N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- FINS Finance/Investors Services
- Sector
- SKYE Health Care
- FINS Finance
- Exchange
- SKYE Nasdaq
- FINS Nasdaq
- Market Cap
- SKYE 73.4M
- FINS N/A
- IPO Year
- SKYE N/A
- FINS N/A
- Fundamental
- Price
- SKYE $4.52
- FINS N/A
- Analyst Decision
- SKYE Buy
- FINS
- Analyst Count
- SKYE 6
- FINS 0
- Target Price
- SKYE $16.60
- FINS N/A
- AVG Volume (30 Days)
- SKYE 2.0M
- FINS 78.0K
- Earning Date
- SKYE 08-08-2025
- FINS 01-01-0001
- Dividend Yield
- SKYE N/A
- FINS 9.97%
- EPS Growth
- SKYE N/A
- FINS N/A
- EPS
- SKYE N/A
- FINS N/A
- Revenue
- SKYE N/A
- FINS N/A
- Revenue This Year
- SKYE N/A
- FINS N/A
- Revenue Next Year
- SKYE N/A
- FINS N/A
- P/E Ratio
- SKYE N/A
- FINS N/A
- Revenue Growth
- SKYE N/A
- FINS N/A
- 52 Week Low
- SKYE $1.14
- FINS $11.61
- 52 Week High
- SKYE $7.60
- FINS $12.57
- Technical
- Relative Strength Index (RSI)
- SKYE 74.70
- FINS 61.73
- Support Level
- SKYE $3.41
- FINS $12.71
- Resistance Level
- SKYE $5.75
- FINS $12.84
- Average True Range (ATR)
- SKYE 0.60
- FINS 0.13
- MACD
- SKYE 0.17
- FINS 0.05
- Stochastic Oscillator
- SKYE 69.27
- FINS 94.92
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.